Background: The efforts to treat localized scleroderma, including therapies with potentially
hazardous side effects, are often unsatisfactory. Recently, PUVA-bath photochemotherapy …

In the present study, we examined the ultrastructural alterations in collagen fibrils clinically
softened by ultraviolet‐A1 (UVA1, 340–400 nm) therapy and psoralen plus long‐wave …

Background: Localized scleroderma is known to be resistant to therapies. Recently, it has
been reported that bath PUVA photochemotherapy is effective for treating this dermatosis …

Background The first reports of the application of ultravioletA1 (UVA1) phototherapy for
scleroderma go back only to 1995, but since then, several studies have proven its …

Abstract Systemic sclerosis (scleroderma)(SSc) is a rare autoimmune disorder characterized
by excessive production of collagen. Extracorporeal photopheresis (photochemotherapy …

Connective‐tissue disorders, which include lupus erythematosus, morphoea/scleroderma
and dermatomyositis, are characterized by cutaneous manifestations that are sometimes …

To the Editor, The introduction of phototherapy has substantially changed the therapeutic
response of localized scleroderma (LS). Systemic agents have been proposed for the …

Background: Numerous treatment modalities, some with potentially hazardous side effects,
are currently used for morphea (M) and systemic sclerosis (SS) with limited success. Low …

Several distinct entities associated with dermal fibrosis can mimic scleroderma/systemic
sclerosis. The list of sclerodermalike conditions or scleroderma variants includes …

BACKGROUND: Recent studies suggest that ultraviolet (UV) A1 phototherapy is an effective
treatment for localized scleroderma (LS); however, the optimum UVA1 dose remains to be …